V1RH13 Inhibitors
V1RH13 inhibitors refer to a class of chemical agents designed to selectively interact with and inhibit the function of a specific biological target identified as V1RH13. This target is typically a protein or enzyme that plays a role in a particular biochemical pathway within an organism. The inhibitors work by binding to the active site or another critical region of the V1RH13 protein, which can impede its natural activity. This binding is often highly specific, meaning that the inhibitor is shaped in such a way that it fits into a particular region of V1RH13 much like a key fits into a lock. The specificity is crucial for ensuring that the inhibitor does not interact with other proteins in a way that could disrupt other physiological processes. The design of these inhibitors is a sophisticated process that involves understanding the structure and function of the V1RH13 protein at a molecular level.
The development of V1RH13 inhibitors is grounded in a complex interplay of disciplines, including chemistry, biochemistry, and molecular biology. Researchers utilize techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy to determine the three-dimensional structure of the V1RH13 protein. Once the structure is known, chemical compounds can be designed or discovered that interact with the protein in a way that inhibits its function. These compounds often mimic the substrate or ligand that the protein normally interacts with, but with modifications that prevent the protein from performing its usual role. Computational methods, like molecular docking and virtual screening, are also employed to predict how potential inhibitors could interact with the protein and to refine their structures for increased efficacy and specificity. The process of designing V1RH13 inhibitors is iterative, with successive rounds of synthesis and testing used to improve the compounds.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which indirectly decreases the activity of ERK1/2. As V1RH13 is likely to be involved in the ERK1/2 signaling pathway, inhibition of MEK by PD 98059 would reduce the phosphorylation and activity of ERK1/2, leading to a downregulation of V1RH13 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway. It binds to the ATP binding site of PI3K, preventing its activity. If V1RH13 functions downstream of PI3K/Akt signaling, LY294002's inhibition of this pathway would result in reduced activation of V1RH13. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly binds to PI3K and inhibits its activity. This would lead to a decrease in downstream signaling, potentially reducing V1RH13 activity if it is a downstream effector in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that binds to the FKBP12 and the mTOR complex (mTORC1), which is involved in cell growth and proliferation. Inhibition of mTORC1 by rapamycin could decrease the activity of V1RH13 if it is regulated by the mTOR signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in stress responses. If V1RH13 is activated by p38 MAPK-mediated signaling, then inhibition by SB203580 would reduce V1RH13 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK signaling pathway, which affects processes like apoptosis and cell differentiation. Inhibition of JNK by SP600125 could lead to decreased V1RH13 activity if V1RH13 is part of this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. Through the inhibition of MEKs, U0126 could reduce ERK-mediated activation of V1RH13. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases, which play roles in various signaling pathways, including cell proliferation and survival. If V1RH13 is activated by Src family kinases, PP2-mediated inhibition would suppress V1RH13 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. If V1RH13 activity is modulated by EGFR signaling, then inhibition by gefitinib would result in decreased V1RH13 activity due to reduced EGFR signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases and Bcr-Abl. If V1RH13 is regulated by these kinases, inhibition by dasatinib would lead to decreased V1RH13 activity. | ||||||